Skip to main content
. 2024 Mar 19;15:1356575. doi: 10.3389/fneur.2024.1356575

Table 1.

Demographics and comorbidities.

AD Delirium Controls Significance
N 33 16 22
Age 76 (73–79) 79.5 (74–87) 73 (64–79) 0.0759 (Kruskal–Wallis)
Median (95% CI)
Sex 14/19 9/7 14/8 0.281 (Fisher)
M/F
Premorbid comorbidities
Neurologic 31 (94%) 16 (100%) 19 (86%) 0.256 (Fisher)
Cortical atrophy 28 (85%) 12 (75%) 4 (18%) <0.001* (Fisher)
Microangiopathy 22 (67%) 14 (88%) 8 (36%) 0.004* (Fisher)
Pre-described dementia 4 (12%) 8 (50%) 0 (0%) <0.001* (Fisher)
PNP 3 (10%) 4 (25%) 12 (54%) <0.001* (Fisher)
Chronic stroke 5 (15%) 5 (31%) 1 (5%) 0.080 (Fisher)
Systemic infections 3 (9%) 7 (44%) 3 (14%) 0.017* (Fisher)
Cardiac 24 (73%) 14 (88%) 13 (59%) 0.153 (Fisher)
Pulmonary 3 (9%) 1 (6%) 3 (14%) 0.773 (Fisher)
Metabolic 17 (52%) 9 (56%) 7 (32%) 0.266 (Fisher)
Oncologic 12 (36%) 3 (19%) 3 (14%) 0.144 (Fisher)
Musculoskeletal 9 (27%) 7 (44%) 10 (45%) 0.331 (Fisher)
Others 13 (39%) 8 (50%) 9 (41%) 0.780 (Fisher)

*p < 0.05.